Xilio Therapeutics, Inc. (XLO) News
Filter XLO News Items
XLO News Results
|Loading, please wait...|
XLO News Highlights
- XLO's 30 day story count now stands at 2.
- Over the past 4 days, the trend for XLO's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest XLO News From Around the Web
Below are the latest news stories about Xilio Therapeutics Inc that investors may wish to consider to help them evaluate XLO as an investment opportunity.
Investment company RiverVest Venture Management LLC (Current Portfolio) buys Xilio Therapeutics Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, RiverVest Venture Management LLC.
WALTHAM, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced that René Russo, Pharm. D., president and chief executive officer, and Marty Huber, M.D., president of research and development and chief medical officer of Xilio Therapeutics, will participate in a virtual fireside chat during the Guggenheim 4th Annual Oncology Day on Thursday, Februa
The big shareholder groups in Xilio Therapeutics, Inc. ( NASDAQ:XLO ) have power over the company. Institutions will...
H.C. Wainwright analyst Michael King reiterated a Buy rating on Xilio Therapeutics (XLO – Research Report) today and set a price target of $36.00. The company's shares closed last Thursday at $13.62. According to TipRanks.com, King is a 4-star analyst with an average return of 13.4% and a 42.8% success rate. King covers the Healthcare sector, focusing on stocks such as Sonnet BioTherapeutics Holdings, Intellia Therapeutics, and Werewolf Therapeutics. Currently, the analyst consensus on Xilio Therapeutics is a Strong Buy with an average price target of $34.75.
Xilio Therapeutics Announces Initiation of Patient Dosing in Phase 1/2 Clinical Trial of XTX202 for the Treatment of Patients with Solid Tumors
WALTHAM, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced that the first patient has been dosed in the company’s Phase 1/2 clinical trial evaluating XTX202 for the treatment of solid tumors. XTX202 is a modified form of IL-2 that is designed to localize activity in the tumor microenvironment (TME), with the goal of overcoming the known tolera
Analysts Offer Insights on Healthcare Companies: ObsEva SA (OBSV), Bionomics Ltd ADR (BNOX) and Xilio Therapeutics (XLO)
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on ObsEva SA (OBSV – Research Report), Bionomics Ltd ADR (BNOX – Research Report) and Xilio Therapeutics (XLO – Research Report) with bullish sentiments. ObsEva SA (OBSV) In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on ObsEva SA, with a price target of $15.00. The company's shares closed last Friday at $1.94, close to its 52-week low of $1.93. According to TipRanks.
WALTHAM, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced the appointment of Yuan Xu, Ph.D., to its board of directors. “Yuan is an industry veteran who brings broad, strategic leadership experience as a private and public company CEO, and deep technical expertise, including leading manufacturing scale-up at some of the world’s most successfu
Anticipate First Patient Dosing in Phase 1/2 Clinical Trial for XTX202, a Tumor-Selective IL-2, in First Quarter of 2022 Advancing Phase 1/2 Clinical Trial for XTX101, a Tumor-Selective Anti-CTLA-4 Successfully Closed IPO in Fourth Quarter of 2021, Raising Approximately $130 Million in Gross Proceeds to Advance Pipeline of Tumor-Selective Immuno-Oncology Programs WALTHAM, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-sel
Xilio Therapeutics Announces Preclinical Data Demonstrating Anti-Tumor Activity and Tolerability of XTX301, a Tumor-Selective IL-12, at Society for Immunotherapy in Cancer Annual Meeting
WALTHAM, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq:XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for patients with cancer, today announced data from preclinical studies of XTX301, an engineered tumor-selective interleukin-12 (IL-12) product candidate, demonstrating selective anti-tumor activity and favorable tolerability with minimal systemic activity. These data are highlighted in a poster at the Society for Immunotherapy in C
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform. Axon Enterprise The Trad